Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

SIOGEN And Veeda Sign Deal on Doxorubicin

By Drug Discovery Trends Editor | May 7, 2010

SIOGEN Biotech, an innovative leader in the field of silicon-based nanoparticle drug delivery and targeting, and Veeda Clinical Research, a global clinical research organisation, signed a strategic partnership agreement at the BIO conference in Chicago to develop a new nanoparticle formulation of Doxorubicin to treat cancer.

The Minister of Science, Technology and Innovation of Malaysia, Datuk Seri. Dr. Maximus Johniti Ongkili was present to witness the signing of the deal, highly significant in the progression of the Malaysian biotechnology sector.

Under the terms of the agreement, SIOGEN will use its patented Siosomes drug delivery and targeting technology to encapsulate Doxorubicin, a drug used for cancer treatment, and Veeda will undertake Phase 1/2 clinical trials of this formulation.

Doxorubicin is an established drug, which is used in chemotherapy for the treatment of leukemias, lymphomas and other cancers. In the past, pegylated liposome formulations of doxorubicin presented with adverse side effects that limited their dosage and efficacy. Encapsulation of Doxorubicin in Siosomes is designed to increase efficacy of the drug through targeted delivery to the site of disease and decrease adverse effects by lowering the exposure of the drug to the tissues and cells.

Commenting on the partnership, Dr Shermal Perera, Managing Director of SIOGEN said: “We are delighted to enter into a strategic partnership with Veeda Clinical Research for the encapsulation of Doxorubicin. This partnership will allow us to explore the advantages of our proprietary Siosomes technology for the targeted delivery of chemotherapeutic compounds. Our agreement with Veeda will capitalise on their significant clinical expertise to advance this product beyond the phase I/II clinical trials.” 

Dr Maurice Cross, Group Medical Director of Veeda Clinical Research reflected that this agreement demonstrated the changes which are occurring in the nature of Clinical Research Organisations such as Veeda.  He said: “In the past were merely providers of trials services, now we have to bring additional value to our client relationships. One way we can do this is by embracing innovative technologies such as that offered by SIOGEN and offering them to our own client base as solutions to their problems.  Thus we become brokers of scientific technology and bring something quite new to the table.”

Datuk Seri Dr. Maximus also commented: “Following extensive Government investment in our growing biotech sector, this agreement is a showcase of the enormous talent found in Malaysian companies and underlines the growing importance of the Malaysian Biotechnology industry in the global arena.”

Date: May 3, 2010
Source: Veeda Clinical Research 

 


Filed Under: Drug Discovery

 

Related Articles Read More >

If Trump gets Europe to pay more for drugs, more new medicines could follow — eventually
Antibody - visual concept of immune System - 3D illustration
Fresenius picks the biosimilars, WuXi Biologics builds them in a deal covering up to 37 candidates
Physician in a white coat reviewing information on a tablet with a patient in an exam room.
What real-world data shows about current cancer care
Roche Towers, Basel, Switzerland
Roche picks cancer targets, Hansoh builds the ADCs in deal with $400 million upfront
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Drug Delivery Business News
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Pharmaceutical Processing World
  • R&D World
  • Subscribe to our E-Newsletter
  • About Us
  • Contact Us

Copyright © 2026 Arrowfly LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of Arrowfly
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Views
    • Webinars
    • PharmSci360
  • Pharma 50
    • 2026 Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE